Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results forARIA
8.22
+0.55 (7.17%)
After Hours: 8.22 0.00 (0.00%)
Jul 28, 5:02p.m. GMT-4  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.66 - 8.29
52 week 4.90 - 9.89
Open 7.89
Vol / Avg. 4.29M/2.38M
Mkt cap 1,463.14M
P/E     -
Div/yield     -
EPS -0.88
Shares 188.67M
Beta 1.44
Inst. own 80%
Aug 5, 2015
Q2 2015 ARIAD Pharmaceuticals Inc Earnings Release - 9:30a.m. GMT-4 - Add to calendar
Aug 5, 2015
Q2 2015 ARIAD Pharmaceuticals Inc Earnings Call - 8:30a.m. GMT-4 - Add to calendar
Jul 23, 2015
ARIAD Pharmaceuticals Inc Annual Shareholders Meeting
Jun 25, 2015
ARIAD Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 10, 2015
ARIAD Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 4, 2015
ARIAD Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
May 7, 2015
Q1 2015 ARIAD Pharmaceuticals Inc Earnings Release
May 7, 2015
Q1 2015 ARIAD Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -219.57% -154.25%
Operating margin -207.15% -151.97%
EBITD margin - -143.61%
Return on average assets -35.68% -33.36%
Return on average equity -355.50% -122.11%
Employees 379 -
CDP Score - -

Address

26 LANDSDOWNE ST
CAMBRIDGE, MA 2139
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Officers and directors

Harvey J. Berger M.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Edward M. Fitzgerald Chief Financial Officer, Executive Vice President, Treasurer
Age: 60
Bio & Compensation  - Reuters
Martin J. Duvall Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 54
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs
Age: 47
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Frank G. Haluska M.D., Ph.D. Senior Vice President - Clinical Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Wayne R. Wilson Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Athanase Lavidas Ph.D. Director
Age: 67
Bio & Compensation  - Reuters